Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Emory University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04883437CT.gov Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | — | Recruiting | — | — | — |
NCT04578600CT.gov CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | — | Completed | — | — | — |
NCT03010358CT.gov Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoplasmacytic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obinutuzumab (this asset) | Emory University | P2 | B · 63 |
| Rituximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cyclophosphamide | Affiliated Hospital to Academy of Military Medical Sciences | P3 | BB |
| Bendamustine | City of Hope Medical Center | P3 | BB |
| Fludarabine | Affiliated Hospital to Academy of Military Medical Sciences | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Prednisone | National Cancer Institute (NCI) | P3 | BB |
| Pembrolizumab | Celldex Therapeutics | P2 | B |
| Ibrutinib | National Cancer Institute (NCI) | P2 | B |
+42 more in the Lymphoplasmacytic Lymphoma cohort
Other indications for Obinutuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Richter Transformation | — | P2 | BB · 71 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 71 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obinutuzumab in Lymphoplasmacytic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obinutuzumab-lymphoplasmacytic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →